ReviewFrontiers in oncology2022
Advances in Stigmasterol on its anti-tumor effect and mechanism of action.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 85 citations in OpenAlex.
- Phytosterols in human health: Biochemical mechanisms of action and disease-modulating effects.World journal of biological chemistry · 2026Review
- Exploring the mechanism of stigmasterol against androgenetic alopecia using geometry optimization, network pharmacology, molecular docking, and molecular dynamics studies.Scientific reports · 2026Article
- Phytochemical, antioxidant, and antimicrobial properties ofJournal of food science and technology · 2026Article
- Chemical Composition and Biological Activities of Diverse Products fromPharmaceuticals (Basel, Switzerland) · 2026Review
- Primary Metabolites in ThreeLife (Basel, Switzerland) · 2026Article
- Anticancer Molecular Mechanisms of Phytosterols: An Updated Review on Clinical Trials.Food science & nutrition · 2026Review
- Stigmasterol, the Active Ingredient in Huanglian Decoction, Inhibits the MAOA-NF-κB-MLCK Pathway to Improve the Inflammation in Rats With Reflux Esophagitis.Endocrine, metabolic & immune disorders drug targets · 2026Article
- AI-assisted identification of innovative phytochemicals from Aizoon canariense aimed at brachyury protein in chordoma: a computational strategy.Scientific reports · 2025Article
- Integrating network pharmacology, molecular docking, and bioinformatics to explore the mechanism of sparganii rhizoma in the treatment of laryngeal cancer.Molecular diversity · 2025Article
- Kaempferols from Echinacea purpurea demonstrate anti-cancer potential by targeting anexelekto in breast cancer therapy using chemoinformatics approach.Discover oncology · 2025Article
- Molecular Insights into the Biomedical Applications ofInternational journal of molecular sciences · 2025Review
- Targeting Gut Microbiota to Combat Vascular Aging and Cardiovascular Disease: Mechanisms and Therapeutic Potential.Nutrients · 2025Review
- Unveiling the Phytochemical Profile and Anti-Cancer Potential ofFood science & nutrition · 2025Article
- Article
- Review
- Stigmasterol as a ptotential phytotherapeutic agent for benign prostatic hyperplasia: modulation of inflammation, oxidative stress, and apoptosis.Molecular biology reports · 2025Article
- Phytochemical analysis of leaf extract of Piper nigrum and investigation of its biological activities.Inflammopharmacology · 2025Article
- A Comprehensive Review on Chemical Structures and Bioactivities ofJournal of fungi (Basel, Switzerland) · 2025Review
- Timbe (Pharmaceuticals (Basel, Switzerland) · 2025Article
- In Vitro Studies of the Effect of Oil Emulsions from Transgenic Flax Varieties on the Treatment of Wound Healing and Care of Human Skin with the Tendency to Inflammation.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stigmasterol is a phytosterol derived from multiple herbaceous plants such as herbs, soybean and tobacco, and it has received much attention for its various pharmacological effects including anti-inflammation, anti-diabetes, anti-oxidization, and lowering blood cholesterol. Multiple studies have revealed that stigmasterol holds promise as a potentially beneficial therapeutic agent for malignant tumors because of its significant anti-tumor bioactivity. It is reported that stigmasterol has anti-tumor effect in a variety of malignancies (e.g., breast, lung, liver and ovarian cancers) by promoting apoptosis, inhibiting proliferation, metastasis and invasion, and inducing autophagy in tumor cells. Mechanistic study shows that stigmasterol triggers apoptosis in tumor cells by regulating the PI3K/Akt signaling pathway and the generation of mitochondrial reactive oxygen species, while its anti-proliferative activity is mainly dependent on its modulatory effect on cyclin proteins and cyclin-dependent kinase (CDK). There have been multiple mechanisms underlying the anti-tumor effect of stigmasterol, which make stigmasterol promising as a new anti-tumor agent and provide insights into research on its anti-tumor role. Presently, stigmasterol has been poorly understood, and there is a paucity of systemic review on the mechanism underlying its anti-tumor effect. The current study attempts to conduct a literature review on stigmasterol for its anti-tumor effect to provide reference for researchers and clinical workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.